251 related articles for article (PubMed ID: 21621406)
41. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
[TBL] [Abstract][Full Text] [Related]
42. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer.
Cascinu S; Staccioli MP; Gasparini G; Giordani P; Catalano V; Ghiselli R; Rossi C; Baldelli AM; Graziano F; Saba V; Muretto P; Catalano G
Clin Cancer Res; 2000 Jul; 6(7):2803-7. PubMed ID: 10914727
[TBL] [Abstract][Full Text] [Related]
43. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
44. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
45. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
Chan AK; Wong A; Jenken D; Heine J; Buie D; Johnson D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):665-77. PubMed ID: 15708244
[TBL] [Abstract][Full Text] [Related]
46. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B
Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904
[TBL] [Abstract][Full Text] [Related]
47. [Genetic instability of gene nm23H1 in colon cancer of Chinese patient].
Su ZH; Li JC
Shi Yan Sheng Wu Xue Bao; 2003 Oct; 36(5):325-9. PubMed ID: 14724942
[TBL] [Abstract][Full Text] [Related]
48. Clinical implications of fibroblast activation protein in patients with colon cancer.
Henry LR; Lee HO; Lee JS; Klein-Szanto A; Watts P; Ross EA; Chen WT; Cheng JD
Clin Cancer Res; 2007 Mar; 13(6):1736-41. PubMed ID: 17363526
[TBL] [Abstract][Full Text] [Related]
49. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
50. Absence of MMP2 expression correlates with poor clinical outcomes in rectal cancer, and is distinct from MMP1-related outcomes in colon cancer.
Wong JC; Chan SK; Schaeffer DF; Sagaert X; Lim HJ; Kennecke H; Owen DA; Suh KW; Kim YB; Tai IT
Clin Cancer Res; 2011 Jun; 17(12):4167-76. PubMed ID: 21531813
[TBL] [Abstract][Full Text] [Related]
51. 1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer.
Mayrhofer M; Kultima HG; Birgisson H; Sundström M; Mathot L; Edlund K; Viklund B; Sjöblom T; Botling J; Micke P; Påhlman L; Glimelius B; Isaksson A
BMC Cancer; 2014 Nov; 14():872. PubMed ID: 25420937
[TBL] [Abstract][Full Text] [Related]
52. Prognostic relevance of estrogen receptor-α Ser167 phosphorylation in stage II-III colon cancer patients.
López-Calderero I; Carnero A; Astudillo A; Palacios J; Chaves M; Benavent M; Limón ML; Garcia-Carbonero R
Hum Pathol; 2014 Dec; 45(12):2437-46. PubMed ID: 25283475
[TBL] [Abstract][Full Text] [Related]
53. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.
Kennedy RD; Bylesjo M; Kerr P; Davison T; Black JM; Kay EW; Holt RJ; Proutski V; Ahdesmaki M; Farztdinov V; Goffard N; Hey P; McDyer F; Mulligan K; Mussen J; O'Brien E; Oliver G; Walker SM; Mulligan JM; Wilson C; Winter A; O'Donoghue D; Mulcahy H; O'Sullivan J; Sheahan K; Hyland J; Dhir R; Bathe OF; Winqvist O; Manne U; Shanmugam C; Ramaswamy S; Leon EJ; Smith WI; McDermott U; Wilson RH; Longley D; Marshall J; Cummins R; Sargent DJ; Johnston PG; Harkin DP
J Clin Oncol; 2011 Dec; 29(35):4620-6. PubMed ID: 22067406
[TBL] [Abstract][Full Text] [Related]
54. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.
Maak M; Simon I; Nitsche U; Roepman P; Snel M; Glas AM; Schuster T; Keller G; Zeestraten E; Goossens I; Janssen KP; Friess H; Rosenberg R
Ann Surg; 2013 Jun; 257(6):1053-8. PubMed ID: 23295318
[TBL] [Abstract][Full Text] [Related]
55. Common cancer stem cell gene variants predict colon cancer recurrence.
Gerger A; Zhang W; Yang D; Bohanes P; Ning Y; Winder T; LaBonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; El-Khoueiry A; Kahn M; Lenz HJ
Clin Cancer Res; 2011 Nov; 17(21):6934-43. PubMed ID: 21918173
[TBL] [Abstract][Full Text] [Related]
56. [Risk factors for recurrence of stage II colon cancer].
Okamoto Y; Kawamura T; Sakai T; Mitsutsuji M; Oshikiri T; Kamoda Y; Takase N
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1633-7. PubMed ID: 21996958
[TBL] [Abstract][Full Text] [Related]
57. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
58. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
[TBL] [Abstract][Full Text] [Related]
59. Clinicopathological risk factors of Stage II colon cancer: results of a prospective study.
Santos C; López-Doriga A; Navarro M; Mateo J; Biondo S; Martínez Villacampa M; Soler G; Sanjuan X; Paules MJ; Laquente B; Guinó E; Kreisler E; Frago R; Germà JR; Moreno V; Salazar R
Colorectal Dis; 2013 Apr; 15(4):414-22. PubMed ID: 22974322
[TBL] [Abstract][Full Text] [Related]
60. Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Sveen A; Nesbakken A; Ågesen TH; Guren MG; Tveit KM; Skotheim RI; Lothe RA
Clin Cancer Res; 2013 Dec; 19(24):6669-77. PubMed ID: 24166914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
